The Role of Antidepressants or Antipsychotics in Preventing Psychosis
Status: | Completed |
---|---|
Conditions: | Psychiatric |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | 12 - 25 |
Updated: | 5/5/2014 |
Start Date: | October 2012 |
End Date: | December 2013 |
Contact: | Michael L Birnbaum, MDCM |
Email: | mbirnbau@chpnet.org |
Phone: | 212-523-2932 |
This is a randomized, controlled pilot study comparing the antidepressant fluoxetine with
the second generation antipsychotic aripiprazole in approximately 10 subjects aged 12-25 at
risk for developing psychosis.
Our primary hypotheses are that compared to aripiprazole, fluoxetine will be better
tolerated and will lead to greater improvement in symptoms at the end of 6 months of
treatment.
the second generation antipsychotic aripiprazole in approximately 10 subjects aged 12-25 at
risk for developing psychosis.
Our primary hypotheses are that compared to aripiprazole, fluoxetine will be better
tolerated and will lead to greater improvement in symptoms at the end of 6 months of
treatment.
Inclusion Criteria:
- 12-25 years of age (inclusive)
- Able to understand and speak English
- Have at least one sub-threshold positive psychotic symptom that is moderate,
moderately severe, or severe
Exclusion Criteria:
- Lifetime diagnosis of an Axis I psychotic disorder: schizophreniform disorder;
schizophrenia; schizoaffective disorder; bipolar disorder; or major depression with
psychotic features
- Current psychosis
- Current diagnosis of Major Depressive Disorder, single episode or recurrent, severe
without psychotic features
- Lifetime diagnosis of substance abuse or dependence (excluding nicotine)
- Current stimulant treatment
- Any significant medical condition that contra-indicates treatment with either
aripiprazole or fluoxetine, including history of neurological, neuroendocrine or
other medical condition known to affect the brain
- Estimated intelligence quotient < 70
We found this trial at
1
site
Click here to add this to my saved trials